Werewolf Therapeutics, Inc. (NASDAQ:HOWL) Receives Average Rating of “Hold” from Brokerages

Werewolf Therapeutics, Inc. (NASDAQ:HOWL) has earned an average rating of “Hold” from the seven ratings firms that are currently covering the firm, Marketbeat reports. One research analyst has rated the stock with a sell recommendation, four have assigned a hold recommendation and two have given a buy recommendation to the company. The average 12-month price objective among analysts that have issued a report on the stock in the last year is $3.75.

A number of equities research analysts recently issued reports on HOWL shares. Citigroup cut shares of Werewolf Therapeutics from a “market outperform” rating to a “market perform” rating in a report on Friday, December 19th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Werewolf Therapeutics in a research note on Wednesday, January 21st. Bank of America cut their price objective on Werewolf Therapeutics from $8.00 to $7.00 and set a “buy” rating on the stock in a research note on Tuesday, November 18th. Zacks Research cut Werewolf Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Friday, November 21st. Finally, Citizens Jmp lowered shares of Werewolf Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Friday, December 19th.

Werewolf Therapeutics Stock Performance

HOWL stock opened at $0.67 on Tuesday. The firm has a 50 day moving average of $0.67 and a two-hundred day moving average of $1.13. Werewolf Therapeutics has a 12 month low of $0.53 and a 12 month high of $2.38. The company has a market capitalization of $32.53 million, a price-to-earnings ratio of -0.41 and a beta of 0.77. The company has a quick ratio of 3.87, a current ratio of 3.87 and a debt-to-equity ratio of 0.73.

Insider Buying and Selling

In other news, major shareholder Bioventures 2014 L.P. Mpm sold 88,802 shares of Werewolf Therapeutics stock in a transaction dated Monday, November 24th. The stock was sold at an average price of $0.98, for a total value of $87,025.96. Following the transaction, the insider directly owned 5,168,303 shares in the company, valued at approximately $5,064,936.94. The trade was a 1.69% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, Director Luke Evnin sold 108,606 shares of the business’s stock in a transaction dated Monday, December 29th. The stock was sold at an average price of $0.61, for a total value of $66,249.66. Following the transaction, the director directly owned 2,550,674 shares of the company’s stock, valued at $1,555,911.14. This represents a 4.08% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold 2,157,968 shares of company stock worth $1,830,115 in the last quarter. 23.60% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Werewolf Therapeutics

Several hedge funds have recently modified their holdings of the business. AQR Capital Management LLC bought a new position in Werewolf Therapeutics during the first quarter worth $79,000. Y Intercept Hong Kong Ltd bought a new position in shares of Werewolf Therapeutics during the 2nd quarter worth about $92,000. Quadrature Capital Ltd acquired a new position in shares of Werewolf Therapeutics during the second quarter valued at about $28,000. Marshall Wace LLP acquired a new position in shares of Werewolf Therapeutics during the second quarter valued at about $113,000. Finally, Qube Research & Technologies Ltd acquired a new stake in Werewolf Therapeutics during the second quarter worth about $48,000. 64.84% of the stock is owned by institutional investors.

Werewolf Therapeutics Company Profile

Werewolf Therapeutics, Inc (NASDAQ: HOWL) is a clinical-stage biotechnology company focused on the development of next-generation immunotherapies for the treatment of solid tumors. The company’s proprietary Conditional Activation Platform is designed to keep therapeutic molecules inert in healthy tissues and selectively activate them within the tumor microenvironment, aiming to enhance anti-tumor efficacy while minimizing systemic toxicity.

Leveraging this platform, Werewolf Therapeutics is advancing multiple programs that include conditionally activated cytokine candidates and bi-specific antibody constructs.